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Increased production of reactive oxygen species and failure of the antioxidant defense system are con-
sidered to play a central role in the pathogenesis of cardiovascular disease. The transcription factor
nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a key master switch controlling the expression of
antioxidant and protective enzymes, and was proposed to participate in protection of vascular and
cardiac function. This study was undertaken to analyze cardiac and vascular phenotype of mice lacking
Nrf2. We found that Nrf2 knock out (Nrf2 KO) mice have a left ventricular (LV) diastolic dysfunction,
characterized by prolonged E wave deceleration time, relaxation time and total diastolic time, increased
E/A ratio and myocardial performance index, as assessed by echocardiography. LV dysfunction in Nrf2 KO
mice was associated with cardiac hypertrophy, and a downregulation of the sarcoplasmic reticulum
Ca2þ-ATPase (SERCA2a) in the myocardium. Accordingly, cardiac relaxation was impaired, as demon-
strated by decreased responses to β-adrenergic stimulation by isoproterenol ex vivo, and to the cardiac
glycoside ouabain in vivo. Surprisingly, we found that vascular endothelial function and endothelial nitric
oxide synthase (eNOS)-mediated vascular responses were fully preserved, blood pressure was decreased,
and eNOS was upregulated in the aorta and the heart of Nrf2 KO mice. Taken together, these results show
that LV dysfunction in Nrf2 KO mice is mainly associated with cardiac hypertrophy and downregulation
of SERCA2a, and is independent from changes in coronary vascular function or systemic hemodynamics,
which are preserved by a compensatory upregulation of eNOS. These data provide new insights into how
Nrf2 expression/function impacts the cardiovascular system.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The transcription factor nuclear factor (erythroid-derived 2)-like 2
(Nrf2) is a key master switch controlling the expression of anti-
oxidant and protective enzymes [1–3]. An imbalance between pro-
oxidants and anti-oxidant defense systems, deﬁned as oxidativeInc. This is an open access article u
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orenstraße 5, 40225 Düssel-
e (M.M. Cortese-Krott).stress [4], has been linked to the development of atherosclerosis, as
well as vascular and cardiac dysfunction and maladaptive cardiac
remodeling [5]. Nrf2-target genes and their biochemical pathways
regulate different physiological and pathophysiological processes
including detoxiﬁcation from xenobiotics and heavy metals [3],
cancer [6], neurodegeneration [7], adipocyte differentiation [8],
stroke [9], inﬂammation and related conditions, like metabolic dis-
orders (e.g. diabetes) [10] and vascular aging [11]. Nrf2 knock out
(KO) mice show amarked dysregulation of the biochemical pathways
responsible for maintenance of redox state and defense mechanisms
[3]. Therefore they could be considered as a model of chronic
adaptation of the organism to oxidative stress [3]. From in vitro
studies carried out in vascular cells and cardiomyocytes, it is clear
that activation of Nrf2-dependent pathways exerts a protective effect
against exogenous noxious stimuli, heavy metals and pro-oxidative
damage [12–15]. In vivo activation of Nrf2 by pharmacologicalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Changes in mitral valve Doppler proﬁle of Nrf2 KO mice. (A) Schematic representation of the mitral blood ﬂow as seen in apical four-chamber view. The inset
illustrates the detection window. (B) Analysis of mitral valve Doppler ﬂow. The E peak (or wave) represents passive early diastolic ﬁlling, followed by the A wave, which is
caused by atrial contraction. DT, deceleration time of the E wave; MVET, mitral valve ejection time (representing diastolic ﬁlling time); IVRT, isovolumic relaxation time; IVCT,
isovolumic contraction time and AET, aortic ejection time (representing total systolic ejection time). (C, D) Representative images of a mitral valve Doppler proﬁle in Nrf2 KO
(C) and WT mice (D).
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stimuli [17] protect the heart against ischemia/reperfusion injury,
while lack of Nrf2 fully blocks these cardioprotective effects [16].
Considering the central role of Nrf2 in maintenance of tissue
redox balance, we hypothesized that Nrf2-dependent biochemical
pathways may play a role in preservation of cardiac and vascular
function. In this study we aimed to investigate the cardiac and
vascular phenotype, as well as systemic hemodynamics in Nrf2 KO
mice as compared to WT littermates by using a multilevel trans-
lational approach. Cardiac and endothelial function of these mice
were assessed non-invasively by high-resolution ultrasound, as
done in clinical settings [18,19], and were compared to ex vivo
analysis of cardiac contractility and coronary function in isolated
perfused hearts. Speciﬁcally, left ventricular (LV) diastolic function
was assessed by analyzing transmitral valve Doppler ﬂow, while
endothelial function was measured as ﬂow-mediated dilation
(FMD). We found that Nrf2 KO mice have an impaired LV diastolic
function associated with LV hypertrophy and downregulation ofsarcoplasmic reticulum Ca2þ-ATPase 2a (SERCA2a) in the myo-
cardium. Consistently, we found an impaired myocardial relaxa-
tion, and disturbed responses to pharmacological modulators of
Ca2þhomeostasis (isoproterenol/ouabain), while endothelial
function was fully preserved via upregulation of endothelial nitric
oxide synthase (eNOS). These data provide new insights into how
Nrf2 expression/function impact the cardiovascular system.2. Materials and Methods
2.1. Materials
Unless otherwise speciﬁed, chemicals were purchased from
Sigma-Aldrich Co. LLC. (Deisenhofen, Germany). Materials for
western blotting were purchased from Life technologies (Invitro-
gen, Darmstadt, Germany).
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All experiments were approved by the LANUV according to the
European Convention for the Protection of Vertebrate Animals
used for Experimental and other Scientiﬁc Purposes (Council of
Europe Treaty Series No. 123). Animal care was in accordance with
the institutional guidelines. If not differently speciﬁed, male C57Bl/
6 J mice were used as WT control (The Jackson Laboratory, Bar
Harbor, ME, USA). Nrf2 KO/C57BL6J (BRC No. 01390) mice were
obtained by Rinken (Koyadai, Tsukuba, Ibaraki, Japan) and crossed
for more than 10 generations with C57BL/6 J. Moreover, eNOS KO
mice with C57BL/6 J background were obtained from Dr. Axel
Gödecke (Heinrich Heine University of Düsseldorf, Düsseldorf,
Germany) [20]. For experiments, 5-6 month old male mice were
used.
2.3. Cells
Pooled human umbilical vein endothelial cells (HUVECs) of a
deﬁned lot were obtained from Promocell (Heidelberg, Germany),
cultured under standard conditions at 37 °C with 5% CO2 in a
commercial endothelial culture medium (Promocell) as previously
described [21].
2.4. Measurement of reduced and total glutathione (GSH)
For determination of reduced and total GSH, aorta and heart of
Nrf2 KO mice and WT mice were homogenized in ice cold 0.01 M
HCl and sonicated for 30 s at 4 °C. After centrifugation at
14,000 g for 10 minutes (min) at 4 °C, the supernatant was
mixed with 5% sulfosalicylic acid (2.5% ﬁnal concentration) to
precipitate the proteins, and centrifuged again as described above.
The clear supernatant was used for GSH measurements using the
DetectX Fluorescent Detection Kit (Arbor Assays, Ann Arbor, MI,
USA) following the manufacturer´s instructions. Oxidized glu-
tathione (GSSG) was calculated as (total GSH-Free GSH)/2. More-
over, the ratio of reduced GSH/GSSG was calculated.
2.5. Assessment of cardiac function
Cardiac imaging was carried out by using a high-resolution
ultrasound system (18-38 MHz; Vevo 2100, Visual Sonics Inc.,
Toronto, Canada), and the manufacturer's analysis software. LV
volume, stroke volume (SV), cardiac output (CO) and ejection
fraction (EF) were calculated in B-mode by identiﬁcation of max-
imal and minimal cross-sectional area. Additionally, LV systolic
function was determined as fractional shortening (FS) in the
longitudinal axis. LV diastolic function was measured by analyzing
the characteristic ﬂow proﬁle of the mitral valve Doppler and
tissue Doppler ﬂow (Fig. 1B), which was visualized in apical four-
chamber view. The E deceleration time (DT) was taken from the
maximum of the E wave to its baseline. Mitral valve ejection time
(MVET) represents total diastolic time (duration of diastolic ﬁlling
of the left ventricle) and was analyzed by calculating velocity time
integral of E and A wave. Isovolumic relaxation time (IVRT) was
determined as the interval between aortic valve closure and mitral
valve opening; isovolumic contraction time (IVCT) represents the
interval between mitral valve closure and aortic valve opening.
The myocardial performance index (MPI or Tei-index) [22], which
is an objective parameter incorporating systolic and diastolic time
intervals and deﬁnes global systolic and diastolic ventricular
function, was calculated as the sum of IVRT and IVCT divided by
aortic ejection time ( ¼ mitral valve no ﬂow time) [23]. LV mass
was calculated as ((1.053n((LVEDDþLVPW,EDþ IVS,ED)3-
LVEDD3))n0.8) and further normalized for body weight. Cardiac
mass was also calculated from the ratio between heart weight andbody weight (Table 2).
2.6. Assessment of vascular function and stiffness in vivo
Vascular function was assessed with a Vevo 2100 with a 30–
70 MHz linear array microscan transducer (Visual Sonics). The
method consists in the analysis of changes in vessel diameter in
response to shear stress after vascular occlusion by using a cuff;
this method was developed from a procedure published pre-
viously [24] with substantial modiﬁcations, which allowed us to
measure changes in vessel diameter both during occlusion and
after cuff-release. During the experiment, mice were kept under
1.5-2% isoﬂurane anesthesia, a heart rate of 400–500 bpm, a
breathing rate of about 100 breaths per minute, and a 37 °C body
temperature. The transducer was placed using a stereotactic
holder and was adjusted manually to visualize the arteria iliaca
externa as depicted in supplementary information (SI Fig. S1). The
vessel was identiﬁed by its characteristic blood ﬂow pattern by the
duplex ultrasound method. A vascular occluder (8 mm diameter,
Harvard Apparatus, Harvard, Boston, MA, USA) was placed around
the lower limb. For measurements of vascular function, ﬁrst
baseline images of the vessel were recorded, afterwards the oc-
cluder (positioned above the knee) was inﬂated to 200 mmHg, and
pressure was kept constant for 5 min (Druckkalibriergerät KAL 84,
Halstrup Walcher, Kirchzarten, Germany) to occlude the vessels;
then the occluder was deﬂated to induce shear stress and ﬂow-
mediated dilation (FMD). The diameter of the vessel was de-
termined at the indicated time points (see main text) both during
cuff inﬂation and after cuff release, proximal to the cuff. Changes
in vessel diameter were calculated as percent ratio (%) ¼ [dia-
meter (max) / diameter (baseline)] x 100. Baseline values for WT
were 0.2770.06 mm (n ¼ 12) and for Nrf2 KO 0.2970.04 mm
(n ¼ 14). The maximal percent changes in dilation as compared to
baseline were calculated as Δ% ¼ [diameter (max) – diameter
(baseline) / diameter (baseline)]100. Where indicated, the same
measurements were performed in the presence of the speciﬁc
nitric oxide synthase (NOS) inhibitor 2-ethyl-2-thiopseudourea
hydrobromide (ETU) infused intraperitoneally (i.p. 1.3 mmol/kg/
min) for 30 min before determination of vascular function. In
these experiments baseline measurements were determined both
before and after administration of ETU (WTþETU 0.2170.03 mm
vs. WT untreated 0.2770.05 mm, n ¼ 5; Nrf2 KOþETU
0.2770.03 mm vs. Nrf2 KO untreated 0.2870.05 mm, n ¼ 6).
Vascular stiffness was assessed as pulse wave velocity (PWV) in
the arteria carotis communis as described previously [25] with
some modiﬁcations. B-mode images were obtained by placing the
transducer above the arteria carotis to obtain longitudinal images
of this vessel. Images were acquired proximal and distal to the
carotis bifurcation in M-mode and PW-Doppler, and the distance
between these points was determined (SI Fig. S2). PWV was cal-
culated as a ratio between distance/time interval, determined by
measuring the interval time from the R wave (recorded with the
electrocardiogram) to either systolic notch in M-mode, or alter-
natively to the peak of systolic component in PW Doppler.
2.7. Assessment of vascular function in aortic rings ex vivo
Thoracic aortas were explanted and analyzed in an organ bath
as previously described [26]. Experiments started after an equili-
bration phase of 60 min. Endothelial function was assessed by
administration of cumulative doses of acetylcholine (ACh; 0.1 nM–
10 μM). After washing, vascular contractility was determined by
applying cumulative doses of the α1-adrenergic receptor agonist
phenylephrine (PHE; 0.1 nM  10 μM). Subsequently, NO-depen-
dent vasodilation was induced by applying a cumulative dose of
sodium nitroprusside (SNP; 0.01 pM–10 μM). The half-maximal
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preliminary experiments.
2.8. Assessment of cardiac function in isolated perfused hearts
Mice were anesthetized by i.p. injection of 100 mg/kg ketamine
(Ketanest
s
) and 10 mg/kg xylazine (Rompun
s
), and anticoagulated
with heparin (250 IU i.p.). The heart was explanted and retrograde
perfused at 100 mmHg with a modiﬁed Krebs-Henseleit buffer
containing NaCl (118 mM), KCl (4.7 mM), MgSO4 (0.8 mM),
NaHCO3 (25 mM), KH2PO4 (1.2 mM), glucose (5 mM), pyruvic acid
(1.9 mM) and CaCl2 (2.5 mM) gassed with carbogen gas, as pre-
viously described [27]. Left ventricular pressure (LVP), perfusion
pressure, aortic ﬂow, and heart rate were measured continuously
by using an analog–digital converter (2,000 Hz) and dedicated
software (EMKA Technologies, Paris, France). Experiments started
after an equilibration phase of about 20 min. To assess coronary
endothelial function we induced 20 seconds (s) of ischemia fol-
lowed by 5 min of reperfusion. Bradykinin (5 mmol/ml), adenosine
(1 mmol/ml) and isoproterenol (12 pmol/ml) were infused into the
aortic cannula one after another with 10-15 min washout intervals
in between.
2.9. Assessment of natriuretic peptides, β-MHC, and TNFα in serum
Mice were anesthetized as described above, and blood was
taken from cardiac punction and transferred directly into serum
collection tubes. After 20 min of incubation at room temperature,
tubes were centrifuged at 2,500 g for 3 min, and serum was
frozen and kept at -20 °C until analysis. Atrial natriuretic peptide
(ANP), NTproBNP, β-MHC and TNFα were analyzed using high
sensitive ELISA Kits purchased from Hölzel-Biotech (Köln, Ger-
many) and carried out as by manufacturer's instructions.
2.10. Assessment of systemic hemodynamics
Invasive assessment of hemodynamic parameters was carried
out by using a 1.4 F Millar pressure-conductance catheter (SPR-
839, Millar Instrument, Houston, TX, USA) placed into the left
ventricle through the right carotid artery according to the closed
chest method as described [28]. Pressure was recorded by a Millar
Box and analyzed with LabChart 7 (AD Instruments, Oxford, UK) to
assess LV developed pressure, rate of pressure development
(dP/dtmax) and rate of pressure decrease (dP/dtmin). The effects of
the cardioglycoside ouabain (i.p. 1 nmol/kg) on these parameters,
as well as the effects of NOS inhibition by ETU on systolic and
diastolic pressure (i.p. 1.3 mmol/kg/min as already described) were
also determined.
2.11. Organ explantation for biochemical parameters
Mice were anesthetized as described above. Organs were ex-
planted after systemic perfusion with cold phosphate buffered
solution pH 7.4 and immediately frozen in liquid nitrogen.
2.12. Determination of eNOS-dependent guanylyl cyclase activation
The eNOS-dependent activation of guanylyl cyclase (GC) in
response to carbachol and the resulting increase in intracellular
cGMP concentration was measured by radioimmunoassay (RIA) as
described before [29], with minor modiﬁcations. Explanted aortas
were prepared in Krebs-Henseleit buffer bubbled with carbogen
gas and cutted in rings. The rings were incubated at 37 °C for
10 min, and treated for 3 min with carbachol (30 mM) to stimulate
eNOS-dependent activation of the NO-dependent GC and cGMP
synthesis. Immediately thereafter, aorta fragments were frozen inliquid nitrogen. Frozen samples were homogenized and lysed in
70% ethanol. After centrifugation (14,000 g, 15 min, 4 °C), the
supernatants were dried in a Speed-Vac (Thermoscientiﬁc,
Braunschweig, Germany) and used for measurement of cGMP.
Dried pellets were lyzed in a solution of 0.1% SDS in 0.1 M NaOH
and protein concentration was assessed by Lowry assay (DC Pro-
tein Assay, Bio-Rad).
2.13. Western blot analysis
Organs were weighted, lysed in RIPA buffer (1% NP40, 0.5%
sodium deoxycholate, 0.1% SDS in PBS) containing a cocktail of
protease and phosphatase inhibitors (Pierce) and homogenized at
4 °C by using TissuRuptor (Qiagen, Hilden, Germany) and frozen at
20 °C. Lysates were sonicated for 3 min at 4 °C and centrifuged
at 4,000 g for 10 min at 4 °C. Total protein concentration of the
supernatant was determined by Lowry assay. Samples (80 mg heart
lysate; 20 mg aorta lysate) and HUVECs (positive control, 5 mg)
were loaded in 7% or 3–8% NuPAGE Tris-Acetate pre-cast gels
(Invitrogen) following the manufacturer's instructions. After
transfer onto PVDF membrane Hybond P (Amersham Biosciences,
Munich, Germany), proteins were stained with Ponceau S (SERVA
Electrophoresis GmbH, Heidelberg, Germany). The membranes
were blocked for 2 hours with 5% BSA (Bio-Rad) in T-TBS (10 mM
Tris, 100 mM NaCl, 0.1% Tween) and incubated overnight at 4 °C
with a mouse anti-eNOS (1 : 250, custom made from #624086 anti
eNOS/NOS type III antibody, stock: 1 mg/ml in PBS pH 7.4, BD
Bioscience, Erembodegem, Belgium), a rabbit anti-phospho-eNOS
(Ser1177) (1 : 500; #9571, Cell Signaling, Cambridge, UK), or
monoclonal mouse anti-α-Tubulin (1 : 5,000, #T6199, Sigma-Al-
drich) in T-TBS. After washing for 1 hour in T-TBS, the membranes
were incubated with HRP-conjugated goat anti-mouse or anti-
rabbit antiserum (1 : 5,000; BD Biosciences). The bands were vi-
sualized by autoradiography on Hyperﬁlm ECL (Amersham Bios-
ciences) using SuperSignal West Pico Chemiluminescent Substrate
(Pierce) or SuperSignal West Femto Chemiluminescent Substrate
(Pierce). Band intensity quantiﬁcation was carried out using Im-
ageJ. Further determination of SERCA2a and eNOS/phospho-eNOS
(Ser1177) in heart and aortic tissue as well as GC1α in the aorta
were carried out essentially as described above with following
modiﬁcations: for detection of SERCA2a and NO-GC1α we used a
nitrocellulose membrane, and for blocking and detection we used
Amersham ECL Prime blocking agent and Amersham ECL Select
Western Blotting Detection Reagent in an Image Quant (GE
Healthcare, Freiburg, Germany). We used following antibodies: a
rabbit polyclonal anti-SERCA2a (1 : 4,000, #0814-01, Badrilla Ltd.,
Leeds, UK), rabbit polyclonal anti-GC1α (1 : 1,000, #G4280, Sigma-
Aldrich), mouse monoclonal anti-GAPDH (1 : 4,000, #G8795, Sig-
ma-Aldrich) and rabbit polyclonal anti-actin (1 : 5,000, #A2066,
Sigma-Aldrich).
2.14. Measurement of nitrite and nitrate in mouse plasma
Blood samples were collected by intra-cardiac puncture and
transferred to heparinized tubes. The resulting plasma was ana-
lyzed by HPLC as described previously in detail [30].
2.15. Statistical analysis
If not differently speciﬁed, the results are given as
mean7standard error of the mean (SEM). For repeated mea-
surements, data were analyzed by 1-way or 2-way ANOVA as ap-
propriate followed by Bonferroni's or Sidak's post hoc tests. Where
indicated, unpaired Student's t-test was used to determine if two
groups of data were signiﬁcantly different. Normal distribution
was tested by D'Agostino-Pearson test Comparisons with po0.05
Table 2
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Echocardiographic parameters assessed in vivo by high-resolution ultrasound.
Data are reported as mean7SD; n ¼ number of mice. Differences between the two
groups were calculated by unpaired t-test after testing for normal distribution and
equal variances; po0.05 was considered as signiﬁcant and marked in bold.
Parameter Unit WT Nrf2 KO p
n 10 12 (WT vs. Nrf2
KO)
Weight
Body weight g 3573 3373 0.27
Heart weight mg 200718 214725 0.25
Parameters of cardiac function and mass
Heart Rate BPM 393721 372723 0.056
Cardiac Output ml/min 13.172.7 13.072.6 0.97
Stroke Volume ml 30.675.3 35.876.8 0.09
Ejection Fraction % 50.179.3 41.477.7 0.08
Fractional Shortening % 10.273.2 10.874.4 0.72
LV Mass corrected mg 69.7715.2 88.6717.1 0.054
Endsystolic Volume ml 32.879.8 54.5717.2 0.005











E/A 1.570.3 2.270.6 0.0158
E/E‘ 20.974.3 30.876.7 0.0094
Deceleration Time ms 13.174.4 30.074.5 o0.0001
Diastolic Time (MVET) ms 58.578.9 76.9715.5 o0.0001
Isovolumic Relaxation
Time
ms 17.872.6 23.674.4 0.0046
Isovolumic Contraction
Time
ms 10.274.1 9.973.6 0.893. Results
3.1. Redox imbalance in the heart and vessels of Nrf2 KO mice
To determine whether lack of Nrf2 affects the antioxidant ca-
pacity of the myocardium and vascular tissues, we ﬁrst evaluated
the levels of total glutathione (GSH) and reduced "free" (GSH) in
the tissues of Nrf2 KO mice (Table 1). In aorta we found decreased
total GSH levels, increased GSSG levels, and decreased GSH/GSSG
ratio, as compared to WT mice. In the heart of Nrf2 KO mice, al-
though the levels of total GSH were decreased, we found a com-
pensatory increase in the GSH/GSSG ratio. These results show that
Nrf2 KO mice have decreased GSH-dependent antioxidant and
detoxiﬁcation capacity. These ﬁndings are in line with previous
data showing downregulation of phase II antioxidant enzymes,
including enzymes responsible for the de novo synthesis of GSH in
Nrf2 KO mice [16,31,32].
3.2. Diastolic dysfunction, cardiac hypertrophy and downregulation
of SERCA2a in Nrf2 KO mice in vivo
To analyze the functional consequences of redox dysregulation
in the heart of Nrf2 KO mice, we carried out a non-invasive as-
sessment of cardiac function by high-resolution ultrasound. In
Nrf2 KO mice systolic function is fully preserved, as indicated by
ejection fraction and fractional shortening, which were not sig-
niﬁcantly different as compared to WT littermates (Table 2). Ac-
cordingly, cardiac output (CO) and stroke volume (SV) were also
not signiﬁcantly different in Nrf2 KO as compared to WT mice
(Table 2). To measure LV diastolic function, we visualized the mi-
tral inﬂow by pulse wave Doppler imaging in apical four chamber
view (schematically depicted in Fig. 1A), and analyzed the Doppler
ﬂow proﬁle by quantifying the characteristic waves (Fig. 1B).
Fig. 1C and D show representative pictures of the mitral ﬂow
Doppler proﬁle: the E peak (or wave) represents passive early
diastolic ﬁlling, followed by the A wave, which is caused by atrial
contraction. The overall proﬁle of the ﬂow Doppler waves of Nrf2
KO mice (Fig. 1C) was largely different as compared to WT litter-
mates (Fig. 1D). We found a signiﬁcantly prolonged DT in Nrf2 KO
mice as compared to WT littermates (Fig. 2A), pointing to an im-
paired LV relaxation. Diastolic dysfunction in Nrf2 KO mice was
conﬁrmed by 1.5-fold prolonged MVET and IVRT as compared to
WT littermates, whereas contraction time was not different (Ta-
ble 2). Moreover, the E/A ratio and the E/E´ ratio was 68% increased
in Nrf2 KO mice as compared to WT littermates (Fig. 2A, Table 2).Table 1
Decreased levels of GSH in the heart and in the aorta of Nrf2 KO mice. Data are
reported as mean7SD. n ¼ number of mice; differences between the two groups
were calculated by unpaired t-test after testing for normal distribution and equal
variances. po0.05 was considered as signiﬁcant and marked in bold.
Parameter Unit WT Nrf2 KO p
(WT vs. Nrf2 KO)
Heart n 7 7
Total GSH nmol/mg protein 16.670.4 13.470.2 o0.0001
Free GSH nmol/mg protein 14.570.4 12.170.3 0.0005
GSSG nmol/mg protein 1.170.1 0.670.1 o0.0001
GSH/GSSG 13.470.8 19.771.9 0.0102
Aorta n 7 5
Total GSH nmol/mg protein 16.970.8 12.970.9 0.0086
Free GSH nmol/mg protein 16.770.8 12.170.8 0.0034
GSSG nmol/mg protein 0.170.1 0.470.1 0.0331These results indicate an impaired diastolic ﬁlling of the left
ventricle. Importantly, MPI, which is considered as an objective
parameter of LV function, was also signiﬁcantly increased in Nrf2
KO mice (Fig. 2A), indicating a reduced myocardial relaxation in
Nrf2 KO mice. Heart rate in Nrf2 KO mice was not different as
compared to WT littermates (Table 2).
Diastolic dysfunction in Nrf2 KO mice was associated with LV
hypertrophy, as determined by the signiﬁcant increase of both the
LV mass to body weight ratio, and heart weight to body weight
ratio (Fig. 2A, Table 2). Cardiac hypertrophy was not accompanied
by an increase in circulating natriuretic peptides, as serum levels
of N-terminal of the prohormone brain natriuretic peptide (NT-
proBNP), and atrial natriuretic peptide (ANP) were not different as
compared to WT mice; nor it was related to a pro-inﬂammatory
state, as the number of inﬂammatory cells and levels of circulating
TNFα were not increased in Nrf2 KO mice (SI Tab.S3). In addition,
we found a signiﬁcant decrease in the expression of the SERCA2a
in the myocardium of Nrf2 KO mice as compared to WT mice
(Fig. 2B).
Taken together, Nrf2 KO mice show an impaired LV diastolic
function, correlated to cardiac hypertrophy and downregulation of
SERCA2a.
3.3. Decreased myocardial relaxation and impaired Ca2þ home-
ostasis in the heart of Nrf2 KO mice
Next, we aimed to evaluate whether changes in SERCA2a ex-
pression led to decrease in myocardial relaxation and impaired
Ca2þ homeostasis. We analyzed the effects of β-mimetic stimu-
lation by isoproterenol on cardiac function in a Langendorff system
(Fig. 3A). We found a signiﬁcant reduced response to the appli-
cation of isoproterenol in Nrf2 KO hearts as compared to WT lit-
termates, measured by a decrease in developed pressure (DP)
Fig. 2. LV-diastolic dysfunction, cardiac hypertrophy and decreased expression of SERCA2a in Nrf2 KO mice. (A) Nrf2 KO mice show impaired myocardial relaxation with
prolonged deceleration time (DT), mitral valve ejection time (MVET), increased relaxation time (IVRT), E to A ratio, and myocardial performance index (MPI) as compared to
WT mice. Nrf2 KO mice present cardiac hypertrophy as determined by increased LV-mass to body weight ratio. Parameters were assessed by echocardiography (WT: n ¼ 10,
Nrf2 KO: n ¼ 12); unpaired t-test * po0.05; ** po0.01; **** po0.0001. (B) SERCA2a expression in the myocardium of Nrf2 KO was decreased as compared to WT mice
(SERCA2a is shown in the upper panel and GAPDH was used as loading control; MWM, molecular weight marker. KO ¼ Nrf2 KO mice). Left panel: representative of
3 independent blots. Right panel: densitometric quantiﬁcation (WT: n ¼ 8, Nrf2 KO: n ¼ 8); unpaired t-test; ** po0.01.
Fig. 3. Impaired cardiac relaxation in response to isoproterenol (ex vivo) and ouabain (in vivo) in Nrf2 KO hearts. (A) Developed pressure and dP/dtmin before and after
injection of 12 nM isoproterenol in isolated perfused hearts (WT: n ¼ 8, KO: n ¼ 9); 2-way-ANOVA WT vs. KO po0.001 for both panels. (B) Ouabain (1 nmol/kg i.p.)
increased dP/dtmax and dP/dtmin in WT mice, but not in Nrf2 KO mice as assessed by Millar catheter (WT: n ¼ 7, KO: n ¼ 7). 2-way ANOVAWT vs. Nrf2 KO p o 0.01 for both
panels, Sidak's * po 0.05, *** po0.001, **** po0.0001; unpaired t-test # po0.05.
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Fig. 4. Decreased systolic and diastolic blood pressure in Nrf2 KO mice. (A)
Systolic and (B) diastolic blood pressure were signiﬁcantly decreased in Nrf2 KO
mice as compared to their littermates, as assessed invasively by Millar catheter in
anesthetized mice. Application of ETU results in a signiﬁcant increase in systolic
and diastolic pressure both in WT and Nrf2 KO mice (WT: n ¼ 12; KO: n ¼ 12).
Unpaired t-test ⁎⁎⁎ po0.001; **** po0.0001.
Fig. 5. Fully preserved NOS-dependent endothelial function in Nrf2 KO mice.
(A) Changes in vessel diameter (% ratio vs. baseline diameter) during occlusion
(white panel) and after releasing the cuff in WT mice (black line), in untreated Nrf2
KO mice (blue line), or during continuous infusion of the NOS inhibitor ETU (dark
blue line). The black arrow represents the time point of maximal dilation. Inset: box
plot according to Tukey representing the max percent change in dilation. (WT: n ¼
12; Nrf2 KO: n ¼ 14; Nrf2 KOþETU: n ¼ 6; 1-way ANOVA po0.001, Bonferroni's
*** po0.001; unpaired t-test # po0.05). (B) Changes in vessel diameter (% ratio vs.
baseline diameter) in eNOS KO mice vs. WT mice. (WT: n ¼ 12; eNOS KO: n ¼ 13;
unpaired t-test **** po0.0001).
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dP/dtmax was not different (SI Tab. S1). Adenosine and bradykinin
application increased coronary ﬂow in Nrf2 KO to the same extent
as they did in WT hearts (SI Tab. S1). Intraperitoneal administra-
tion of the cardiac glycoside ouabain increased signiﬁcantly
dP/dtmax and dP/dtmin in WT mice as compared to untreated WT
mice. Instead, the same dose of ouabain did not cause any sig-
niﬁcant response in Nrf2 KO mice as compared to untreated Nrf2
KO mice (Fig. 3B; SI Tab. S2).
Taken together, the reduced response of Nrf2 KO hearts to
isoproterenol ex vivo (Fig. 3A) and ouabain in vivo (Fig. 3B) de-
monstrate that Nrf2 KO mice show a signiﬁcantly impaired cardiac
response to pharmacological regulation of cytosolic Ca2þ home-
ostasis as compared to WT littermates.
3.4. Decreased blood pressure, preserved endothelial function and
eNOS upregulation in the vessels and in the heart of Nrf2 KO mice
Diastolic dysfunction is commonly associated with hyperten-
sion state and/or changes of the total peripheral resistance. Blood
pressure was assessed invasively by using a pressure-con-
ductance-catheter (Millar catheter) inserted in the ascending aorta
of Nrf2 KO mice and WT littermates (Fig. 4 A, B). We found that
systolic and diastolic blood pressure were signiﬁcantly decreased
in Nrf2 KO mice as compared to WT littermates. Application of
NOS inhibitor ETU resulted in a signiﬁcant increase in blood
pressure both in WT- and Nrf2 KO mice.
Vascular endothelial function in Nrf2 KO mice were measured
respectively in vivo (Fig. 5 and SI Fig. S4) as well as ex vivo in aorticrings (SI Fig. S5), while coronary vascular function was measured
in isolated perfused hearts (SI Tab. S1). We found that maximal
dilation of the arteria iliaca externa after 5 min of vascular occlu-
sion was signiﬁcantly increased in Nrf2 KO mice as compared to
WT mice (Fig. 5A), indicating a fully preserved vascular function in
this mice. This response was completely blocked by administration
of the speciﬁc NOS-inhibitor ETU (Fig. 5A). Accordingly, eNOS KO
mice showed no dilatory response to shear stress after occlusion as
compared to WT mice (Fig. 5B), conﬁrming that the FMD response
mainly depends on eNOS-dependent vasodilatory pathways. Data
demonstrating a fully preserved FMD response are consistent with
ex vivo data showing preserved relaxation of aortic rings in Nrf2
KO mice (SI Fig. S5), and preserved coronary endothelial function
in Nrf2 KO isolated perfused hearts (SI Tab. S1). In Nrf2 KO aortic
rings we observed a rightward shift of the PHE dose-response
contractility curve, indicating an impaired contractile response of
Nrf2 KO aortic rings to α-adrenergic stimulation (SI Fig. S5B). As
previously observed in human vessels [19], vascular occlusion in-
duced vasoconstriction in WT (Fig. 5A, white panel) and eNOS KO
Fig. 6. Increases in eNOS expression in the heart and aorta, and eNOS-dependent stimulation of cGMP synthesis in aortic rings of Nrf2 KO mice. (A) Representative
western blot showing increases in eNOS expression in the heart of Nrf2 KO mice; unpaired t-test * po0.05; ** po0.01; MWM, molecular weight marker. HUVECs, human
umbilical endothelial cells (positive control). Right panel: densitometric quantiﬁcation of eNOS levels (vs. loading control) and phosphorylation levels (P-eNOS vs. total
eNOS); (WT: n ¼ 7; Nrf2 KO: n ¼ 7). (B) Representative western blot showing increases in eNOS expression in the the aorta of Nrf2 KO mice (WT: n ¼ 15; Nrf2 KO: n ¼ 14).
Right panel: densitometric quantiﬁcation of western blots; unpaired t-test * p o 0.05; ** po0.01. (C) Increased cGMP production in response to carbachol-mediated
stimulation of eNOS in Nrf2 KO aortic rings as compared to WT controls (2-5 aortic rings/mouse; WT: n ¼ 3; Nrf2 KO: n ¼ 3). 1-way ANOVA po0.0001, Tukey's ** po0.001.
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signiﬁcant vasodilatory response during occlusion (Fig. 5A, white
panel).
Vascular stiffness in Nrf2 KO mice was not different as com-
pared to WT mice, as evidenced by no changes in pulse wave
velocity (PWV) measured in the arteria carotis communis (WT:
0.9170.21 m/s, Nrf2 KO: 0.9370.30 m/s; n ¼ 10). In eNOS KO
mice PWV was signiﬁcantly increased as compared to WT mice
(PWV WT: 0.9970.21 m/s, eNOS KO: 1.6670.83 m/s; n ¼ 6;
t-test p ¼ 0.0238).
Consistent to a fully preserved endothelial function, eNOS ex-
pression was signiﬁcantly up-regulated in the heart (Fig. 6A) and
in the aorta (Fig. 6B) of Nrf2 KO mice as compared to WT litter-
mates. Myocardial and aortic eNOS phosphorylation levels at
Ser1177 were not changed (Fig. 6 A, B). To test for functionality ofeNOS in the vascular wall, we stimulated the eNOS-dependent
cGMP synthesis in aortic explants by treatment with carbachol, as
done before [29]. Interestingly, Nrf2 KO mice showed higher car-
bachol-induced cGMP production as compared to WT mice, con-
ﬁrming that eNOS is functional in the aorta of Nrf2 KO mice
(Fig. 6C). The basal cGMP levels in aorta (Fig. 6C) and heart (SI Fig.
S3B) and the circulating nitrite/nitrate levels (SI Fig. S3A) were not
different as compared to the WT controls.
To summarize, these results demonstrate that Nrf2 KO mice
have a decreased blood pressure, a preserved endothelial function
and an eNOS upregulation in the vessels and in the heart.
4. Discussion
This study was undertaken to analyze cardiac and vascular
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that Nrf2 KO mice have a LV diastolic dysfunction, cardiac hyper-
trophy and impaired Ca2þ homeostasis in the myocardium, while
vascular function is fully preserved via compensatory upregulation
of eNOS. Speciﬁcally, Nrf2 KO mice show 1) preserved systolic
function, but a signiﬁcantly impaired LV diastolic function, with
prolonged E wave, DT, MVET, IVRT, total diastolic time, increased
E/A ratio and increased MPI, as assessed by echocardiography; 2)
LV hypertrophy; 3) downregulation of SERCA2a in the myo-
cardium; 4) an impaired cardiac relaxation, as demonstrated by an
increase in IVRT, and a decreased cardiac response to isoproterenol
ex vivo, and to ouabain in vivo; 5) hypotension, associated with a
fully preserved endothelial function in conduit and coronary ves-
sels; and 6) increased eNOS expression in the aorta and in the
heart. These results clearly show that LV dysfunction in Nrf2 KO
mice is independent from changes in the coronary vascular func-
tion or systemic hemodynamics, and rather caused by cardiac
hypertrophy and downregulation of SERCA2a. These data provide
new insights into how Nrf2 expression/function impacts the car-
diovascular system.
4.1. Diastolic dysfunction, cardiac hypertrophy and dysregulation of
Ca2þ homeostasis in Nrf2 KO mice
There is compelling evidence demonstrating that Nrf2-depen-
dent transcriptional regulation of antioxidant and detoxifying
enzymes play a fundamental protective role in almost any cell and
tissue of the body [11,33], including the heart and the vessels
[8,12,16,31,32,34–37]. In vitro and in vivo studies have shown that
pharmacological activation of Nrf2 protects cardiomyocytes
against increased oxidative and hemodynamic stress, while lack of
Nrf2 blocks these effects [16,32]. An increased production of ra-
dical oxygen species, a decreased availability of reduced glu-
tathione, and decreased expression/activity of protective enzymes
(including glutathione peroxidase, catalase, superoxide dismutase)
have been proposed to participate to the pathogenesis of cardio-
myopathies and heart failure [38,39]. However, a direct molecular
link between redox imbalance, oxidative stress and the molecular
mechanisms leading to cardiac dysfunction and heart failure is
difﬁcult to be deﬁned in detail, also because just few animal
models of oxidative stress-mediated cardiac dysfunction exist.
Nrf2 KO mice can be considered as a model of chronic adap-
tation to oxidative stress, which may allow studying the functional
consequences of a chronic redox imbalance on cardiac and vas-
cular function. By carrying out a comprehensive echocardiographic
evaluation, we here demonstrated that Nrf2 KO mice have a fully
preserved LV systolic function under baseline conditions, as in-
dicated by unchanged CO, EF and SV, but accompanied by an in-
creased MPI (also deﬁned as Tei index [22]), which is an objective
parameter representing both systolic and diastolic function [23].
These results indicated an impaired LV diastolic function in Nrf2
KO mice.
Diastolic dysfunction is mainly characterized by an impaired LV
ﬁlling. Diastolic ﬁlling was evaluated here by a method considered
as standard in the clinical routine, i.e. the transmitral inﬂow
Doppler in apical four chamber view. The ﬁrst hint of impaired
myocardial relaxation in Nrf2 KO mice was a signiﬁcantly pro-
longed DT and a prolonged IVRT. At the cellular level, IVRT re-
presents the time, during which actin-myosin cross-bridges are
returned to a low-force generation state, in a way that relaxation
of the myocardium occurs and initiates diastolic ﬁlling of the
ventricle [40]; therefore, IVRT is considered as the most sensitive
Doppler index to detect an impaired cardiac relaxation [41]. Our
results provide evidence that impaired myocardial relaxation is also
correlated to a dysregulation of Ca2þ handling in the myocardium.
It was shown that Nrf2-dependent signaling pathways play a role inthe regulation of Ca2þ homeostasis in neurons [42]. Moreover, in-
creased oxidative stress impairs Ca2þ-dependent signaling in the
cardiomyocytes [35], and is involved in the dysregulation of ven-
tricular remodeling. Evidence of Ca2þ dyshomeostasis in Nrf2 KO
hearts was presented here. In addition to prolonged IVRT under
baseline conditions in vivo, we found strongly decreased effects of
isoproterenol and ouabain on myocardial relaxation. These drugs
interfere with Ca2þ homeostasis in the cardiomyocytes, respec-
tively inhibiting Ca2þ removal from the cytosol and inducing Ca2þ
overload. Thus, in Nrf2 KO hearts the effects of isoproterenol on DP
and dP/dtmin were lower than in WT mice. Moreover, we found no
effects of ouabain application on dP/dtmax and dP/dtmin in Nrf2 KO
mice, while in WT mice ouabain signiﬁcantly increased both of
those parameters. These results are consistent with decreased ex-
pressional levels of SERCA2a in the myocardium. SERCA2a is a major
regulator of diastolic Ca2þ uptake in the sarcoplasmic reticulum
and contribute to the regulation of Ca2þ homeostasis in cardio-
myocytes [43]. If the expression/activity of SERCA2a is decreased in
the cardiomyocytes, the Ca2þ removal into the sarcoplasmic re-
ticulum is less efﬁcient and results in an impaired relaxation during
diastole as reﬂected by a decrease in IVRT in Nrf2 KO mice. In the
clinical routine LV diastolic dysfunction is graded by severity as
mild, pseudonormal, restrictive, and irreversible. In these mice we
could not distinguish between pseudonormal and restrictive dia-
stolic dysfunction. Cardiac diastolic dysfunction is mainly associated
with an increase in the myocardial mass, as shown here by an in-
crease in both, heart weight to body weight ratio and LV mass to
body weight ratio. Decrease in LV relaxation can be correlated to the
observed LV-hypertrophy, which leads to an increase in oxygen
demand and a concomitant decrease in oxygen supply. These are
associated with an increased stiffness of the cardiomyocytes and
impairment in Ca2þ homeostasis.
Different studies suggest that pro-inﬂammatory cytokines like
TNFα decrease the expression of SERCA2a in the myocardium [44].
We found neither changes in plasma TNFα levels in Nrf2 KO mice
compared to WT littermates, nor any other signs of inﬂammatory
phenotype in these mice. Nrf2 KO on ICR/SV129 background are
known for showing a pro-inﬂammatory state from a certain age
[32] and female mice develop an autoimmune-like disease [45].
The mice used in this study are Nrf2 KO on a C57Bl/6 background,
they grow up normally and do not show any evidence of chronic
inﬂammatory illness like increased leukocytes, edema, skin in-
ﬂammation or strongly reduced body weight.
To summarize, the functional data obtained in vivo and in
isolated working hearts demonstrate an impaired diastolic func-
tion associated with cardiac hypertrophy and decreased expres-
sion of SERCA2a in the myocardium of Nrf2 KO mice. Further
studies should be conducted to analyze the mechanisms under-
pinning the dysregulation of Ca2þ homeostasis in the cardio-
myocytes of Nrf2 KO mice.
4.2. Preserved endothelial function, hypotension and eNOS upregu-
lation in Nrf2 KO mice
A growing body of evidence suggests that increased generation
or decreased detoxiﬁcation of radical oxygen species like super-
oxide radical anion (O2-), hydroxyl radicals and hydrogen per-
oxide lead to oxidative modiﬁcation of target proteins, apoptosis,
and tissue damage [46]. Many enzymatic sources of radical oxygen
species such as membrane oxidase (like NADPH oxidases) or in-
creased production of O2- by the mitochondria have been im-
plicated in vascular damage and increased vascular stiffness [46].
Likewise, decrease in NO bioavailability and endothelial dysfunc-
tion have been linked to eNOS dimer destabilization and enzyme
uncoupling [46], leading to formation of O2- and peroxynitrite as
a result of the reaction of O2- with NO. In vitro experiments have
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role in protection of endothelial cells against oxidative damage [12,
13]. Moreover it was shown that Nrf2-dependent regulation of
gene expression is essential in keeping eNOS in the coupled state
[34], as it regulates the synthesis of the cofactor tetra-
hydrobiopterin in HUVECs [34].
Therefore, in Nrf2 KO mice one would expect to ﬁnd a dys-
functional eNOS, decreased NO bioavailability, endothelial dys-
function, increased vascular stiffness and hypertension. Instead, in
Nrf2 KO mice we found signiﬁcantly decreased blood pressure,
fully preserved shear-stress-dependent ﬂow-mediated vasodila-
tion in vivo and aortic endothelium-dependent relaxation, as well
as fully preserved pharmacological responses to bradykinin and
carbachol in coronary and conduit vessels. Vascular stiffness was
not increased, as demonstrated by lack of changes in pulse wave
velocity. These physiological responses were fully blocked by the
application of the speciﬁc NOS inhibitor ETU, which results in a
signiﬁcant increase in blood pressure and a loss of dilatory re-
sponse after cuff release. Moreover, the basal cGMP levels in the
aorta and in the heart, as well as the circulating nitrite and nitrate
levels in Nrf2 KO mice are not signiﬁcantly different from WT
littermates, indicating a preserved NO bioavailability. On the other
hand, both pharmacological inhibition of NOS in WT mice and
genetic deletion of eNOS lead to a decrease in NO bioavailability
[47], increase in blood pressure and vascular stiffness (assessed by
PWV), as shown here and elsewhere [20,21]. Furthermore, aortic
and myocardial eNOS phosphorylation level (Ser1177) were not
changed in Nrf2 KO mice, suggesting that this post-translational
modiﬁcation is not involved in keeping endothelial function nor-
mal in these mice. These results are supported by a recent pub-
lication showing that eNOS preserves vascular function despite
largely increases in vascular oxidative stress [48]. Taken together,
results demonstrate that increased eNOS expression is a major
underlying mechanism of preserved endothelial function and de-
creased blood pressure in Nrf2 KO mice.
Overexpression of eNOS in the heart and in the vessels of Nrf2
KO mice might be considered as a way to compensate detrimental
changes in vascular tissues due to dysregulation of redox control
and chronic adaptation to the lack of Nrf2. In Nrf2 KO mice the
expression of antioxidant enzymes and enzymes responsible for
the glutathione de novo synthesis are decreased of different extent
in all tissues, including the heart and the vessels [3,16,32,49].
Accordingly, we observed a decrease in total GSH in the aorta and
the heart of these mice, indicating decreased GSH-dependent an-
tioxidant and detoxiﬁcation capacity. Radical oxygen species (re-
leased by treatment with H2O2) have been shown to increase the
eNOS expression and regulate its activity in vascular cells (e.g. via
Ca2þ signaling) [50]. Therefore the molecular mechanisms linking
the lack of Nrf2 to the increased eNOS expression in aorta and
heart could be dependent on the decreased antioxidant and free
radical detoxiﬁcation capacity in Nrf2 KO mice, which may lead to
accumulation of radical oxygen species (including superoxide an-
ion radicals, hydroxyl radical and H2O2). Interestingly, an upregu-
lation of eNOS expression was also found in atherosclerotic vessels
[51]. In our model changes in eNOS expression are also accom-
panied by increase in expression of the NO-sensitive GC1 in the
aorta, and a rightward shift of the NO-induced vasodilation of
aortic rings, which may further contribute to maintenance of
vascular function in Nrf2 KO mice. Although we cannot exclude
that other compensatory redox-dependent mechanisms may
contribute to maintenance of endothelial vascular function and to
decreased blood pressure in mice lacking Nrf2, here we present
compelling evidence showing that the eNOS-dependent patway
plays a major role in compensating redox dysbalance, including
increased eNOS/NO-GC1 expression and pharmacological activa-
tion of the pathway by carbachol, preserved endothelial-dependent vascular relaxation and NO bioavailability. Taken to-
gether, these data demonstrate that eNOS pathway play a central
protective role in vascular protection in Nrf2 KO mice.
While the fundamental role played by eNOS activity in shear-
stress dependent mechanotransduction and blood pressure reg-
ulation is well established [50], the role of eNOS in cardiac con-
traction, relaxation and heart rate is more complex (please refer to
the excellent review by Balligand [50,52]). In the heart, eNOS is
expressed both in the coronary endothelium and the cardiomyo-
cytes [52]. NO endogenously produced in the heart by eNOS (and
in part by the neuronal NOS) is thought to regulate changes in
contractility in response to preload, as well as shear-dependent
myocyte relaxation through cGMP-dependent desensitization of
cardiac myoﬁlaments [50]. At the same time, NO attenuates the
positive inotropic effect of β-adrenergic stimulation and potenti-
ates its lusitropic effect, which allows optimal adaptation of con-
traction-relaxation time intervals (favoring coronary perfusion)
and recruitment of diastolic reserve [50]. This results into an
equivalent of a “smart β-adrenergic blockade” [50], which is re-
sponsible for ﬁne tuning and regulation of cardiac function [50].
A peculiarity of the shear-dependent vascular response in Nrf2
KO mice is the vasodilatory response occurring during cuff oc-
clusion. On the contrary, a vasoconstrictory response was mea-
sured in WT mice (with or without NOS inhibition), as well as in
eNOS KO mice. Similar ﬁndings were described in a comparable
setting in humans [19]. The molecular mechanisms responsible for
vasoconstriction of healthy vessels during occlusion (deﬁned by
Gori et al. as low-ﬂow-mediated constriction) are not fully un-
derstood [19]. Based on pharmacological studies in humans, these
authors proposed that low-ﬂow mediated constriction is NOS-in-
dependent and might be mediated by a coordinated effect of an
increased production of a vasoconstrictor (like endothelin 1) and
the concomitant inhibition of a vasodilator, such as a cytochrome
P450-derived endothelial hyperpolarizing factor (EDHF) and/or
cyclooxygenase products (like prostaglandins). Our ﬁndings in WT
mice treated with NOS inhibitor, as well as eNOS KO mice fully
conﬁrm that the low-ﬂow vasoconstriction is NOS-independent.
On the other hand, the paradoxical vasodilatory response during
cuff-occlusion observed in Nfr2 KO mice may be due to changes in
pathways involving those factors, or due to accumulation of va-
sodilators like H2O2 or O2[26,53], or rather may be a manifes-
tation of altered Ca2þ handling in the vasculature (like observed in
the Nrf2 KO heart) and/or a decreased response to vasoconstric-
tory stimuli of the vessels of these mice (as shown by a blunted
PHE response of Nrf2 KO aortic rings). How exactly the lack of Nrf2
is involved in those changes, which enzymes are involved, and
how overexpression of eNOS and NO production participate in
these responses, these are all new aspects that should be speciﬁ-
cally addressed in the future. The measurement of low-ﬂow and
high ﬂow-dependent changes in rodents by applying the ultra-
sound method described in this paper, together with the ob-
servation that Nrf2 KO mice lack the vasoconstrictor responses
under low ﬂow conditions may allow a deeper understanding of
this phenomena, which until now were only studied in humans.
Taken together, these results show that Nrf2 KO mice have a LV
diastolic dysfunction, which is not related to changes in coronary
vascular function and that eNOS upregulation contributes to pre-
serve vascular endothelial function in these mice.
4.3. Summary, clinical signiﬁcance and future directions
To summarize, we presented compelling evidence that mice
lacking Nrf2 show a LV diastolic dysfunction characterized by a LV
hypertrophy and downregulation of SERCA2a, by an impaired
myocardial relaxation, and by an impaired Ca2þ handling in the
heart. These changes are accompanied by a fully preserved
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increase in eNOS expression in the aorta and in the heart of these
mice. Therefore, Nrf2-dependent pathways may be involved not
only in cardiac remodeling [32] or changes in redox state of car-
diac ﬁbroblasts [15], but also in preserving cardiac function as
shown here. Although LV diastolic dysfunction is a condition oc-
curring in almost 50% of all patients affected by heart failure, and
its prevalence rises by 1% a year [54], the mechanisms re-
sponsible for this medical condition are not fully understood, and
there is a lack of in vivo models of this disease. These results
suggest that Nrf2 KO mice are a useful model for investigating the
mechanisms underpinning the development of diastolic dysfunc-
tion, and put forward novel unexplored questions concerning the
role of Nrf2-dependent biochemical pathways in pathophysiology
of LV diastolic dysfunction and in vascular function, including (but
not limited to) the control of Ca2þ homeostasis in cardiomyocytes
(as described for neurons before [42]), the regulation of vessel
tone during low ﬂow mediated vasoconstriction, and Nrf2-related
regulation of eNOS expression and nitric oxide bioavailability in
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